Disruptive Technology and Hemophilia Care: The Multiple Impacts of Emicizumab

Overview

Journal Res Pract Thromb Haemost

Publisher Elsevier

Date 2021 May 24

PMID 34027289

Citations 8

Authors

Cedric Hermans

Mike Makris

Affiliations

Soon will be listed here.

Abstract

Emicizumab, a bispecific antibody mimicking the action of factor VIII (FVIII), is currently the first and only approved and increasingly accessible disruptive treatment option for hemophilia A, a disease so far mainly treated with frequent intravenous infusions of FVIII concentrates or bypassing agents in case of inhibitor development. Other disruptive treatments are expected to follow, such as agents that rebalance coagulation and gene therapy with the ambition of curing hemophilia. While these treatment options represent major achievements or expectations, their adoption and implementation should consider their multiple direct and indirect, immediate or delayed, consequences on hemophilia care globally. It is these multiple changes, present and future, already visible or hypothetical, that this article intends to review and explore.

Citing Articles

A Sociology of Plasma Proteins - A Technocrat's Perspective.

Farrugia A Int J Soc Determinants Health Health Serv. 2024; 55(1):88-91.

PMID: 39140301 PMC: 11583512. DOI: 10.1177/27551938241264764.

Emicizumab as a Promising Form of Therapy for Type A Hemophilia - A Review of Current Knowledge from Clinical Trials.

Grabowska K, Grzelak M, Zhao L, Pluciennik E, Pasieka Z, Kciuk M Curr Protein Pept Sci. 2024; 25(9):719-737.

PMID: 38797909 DOI: 10.2174/0113892037294674240509094418.

Budget impact and cost-utility analysis of prophylactic emicizumab versus on-demand bypassing agents for adolescent severe haemophilia A patients with inhibitors in India.

Krishnamoorthy Y, Govindan D, Kannan N, Majella M, Hariharan V, Valliappan V Heliyon. 2024; 10(5):e27089.

PMID: 38468938 PMC: 10926073. DOI: 10.1016/j.heliyon.2024.e27089.

In Utero Cell Treatment of Hemophilia A Mice via Human Amniotic Fluid Mesenchymal Stromal Cell Engraftment.

Kao Y, Yen C, Fan H, Chen J, Chen M, Lan Y Int J Mol Sci. 2023; 24(22).

PMID: 38003601 PMC: 10670993. DOI: 10.3390/ijms242216411.

Current status and future prospects of activated recombinant coagulation factor VIIa, NovoSeven®, in the treatment of haemophilia and rare bleeding disorders.

Shima M Ann Hematol. 2023; 103(8):2647-2658.

PMID: 37391649 PMC: 11283401. DOI: 10.1007/s00277-023-05287-2.

References

Franchini M, Mannucci P . Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis. 2012; 7:24. PMC: 3502605. DOI: 10.1186/1750-1172-7-24. View

Jenkins P, Bowyer A, Burgess C, Gray E, Kitchen S, Murphy P . Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline. Haemophilia. 2019; 26(1):151-155. DOI: 10.1111/hae.13903. View

Pierce G, Hart D, Kaczmarek R . Safety and efficacy of emicizumab and other novel agents in newborns and infants. Haemophilia. 2019; 25(5):e334-e335. DOI: 10.1111/hae.13822. View

Susen S, Gruel Y, Godier A, Harroche A, Chambost H, Lasne D . Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra ): Proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in.... Haemophilia. 2019; 25(5):731-737. DOI: 10.1111/hae.13817. View

Mannucci P . Hemophilia therapy: the future has begun. Haematologica. 2020; 105(3):545-553. PMC: 7049365. DOI: 10.3324/haematol.2019.232132. View

Coppola A, Castaman G, Santoro R, Mancuso M, Franchini M, Marino R . Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Haemophilia. 2020; 26(6):937-945. DOI: 10.1111/hae.14172. View

Stonebraker J, Bolton-Maggs P, Brooker M, Evatt B, Iorio A, Makris M . The World Federation of Hemophilia Annual Global Survey 1999-2018. Haemophilia. 2020; 26(4):591-600. DOI: 10.1111/hae.14012. View

Lenting P, Denis C, Christophe O . Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?. Blood. 2017; 130(23):2463-2468. DOI: 10.1182/blood-2017-08-801662. View

Shima M . Bispecific Antibodies and Advances in Non-Gene Therapy Options in Hemophilia. Res Pract Thromb Haemost. 2020; 4(4):446-454. PMC: 7292667. DOI: 10.1002/rth2.12337. View

10.

Konkle B, Shapiro A, Quon D, Staber J, Kulkarni R, Ragni M . BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A. N Engl J Med. 2020; 383(11):1018-1027. DOI: 10.1056/NEJMoa2002699. View

11.

Butterfield J, Hege K, Herzog R, Kaczmarek R . A Molecular Revolution in the Treatment of Hemophilia. Mol Ther. 2019; 28(4):997-1015. PMC: 7132613. DOI: 10.1016/j.ymthe.2019.11.006. View

12.

Pierce G, Haffar A, Ampartzidis G, Peyvandi F, Diop S, El-Ekiaby M . First-year results of an expanded humanitarian aid programme for haemophilia in resource-constrained countries. Haemophilia. 2018; 24(2):229-235. DOI: 10.1111/hae.13409. View

13.

Shima M . [New hemophilia treatment employing a bispecific antibody to factors IXa and X]. Rinsho Ketsueki. 2015; 56(6):623-31. DOI: 10.11406/rinketsu.56.623. View

14.

Holme P, Combescure C, Tait R, Berntorp E, Rauchensteiner S, de Moerloose P . Hypertension, haematuria and renal functioning in haemophilia - a cross-sectional study in Europe. Haemophilia. 2016; 22(2):248-255. DOI: 10.1111/hae.12847. View

15.

Sankar A, Weyand A, Pipe S . The evolution of recombinant factor replacement for hemophilia. Transfus Apher Sci. 2019; 58(5):596-600. DOI: 10.1016/j.transci.2019.08.010. View

16.

Escuriola-Ettingshausen C, Auerswald G, Konigs C, Kurnik K, Scholz U, Klamroth R . Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel. Haemophilia. 2020; 27(3):e305-e313. DOI: 10.1111/hae.14010. View

17.

Raso S, Hermans C . Recombinant factor VIII: past, present and future of treatment of hemophilia A. Drugs Today (Barc). 2018; 54(4):269-281. DOI: 10.1358/dot.2018.54.4.2800622. View

18.

Shima M, Hermans C, de Moerloose P . Novel products for haemostasis. Haemophilia. 2014; 20 Suppl 4:29-35. DOI: 10.1111/hae.12413. View

19.

Blair H . Emicizumab: A Review in Haemophilia A. Drugs. 2019; 79(15):1697-1707. DOI: 10.1007/s40265-019-01200-2. View

20.

Tripodi A, Chantarangkul V, Novembrino C, Scalambrino E, Boscolo-Anzoletti M, Clerici M . Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma. Clin Chem Lab Med. 2020; 59(2):365-371. DOI: 10.1515/cclm-2020-0696. View